Premium
PPP3CB contributes to poor prognosis through activating nuclear factor of activated T‐cells signaling in neuroblastoma
Author(s) -
Shakhova Irina,
Li Yuanyuan,
Yu Fan,
Kaneko Yoshiki,
Nakamura Yohko,
Ohira Miki,
Izumi Hideki,
Mae Takao,
Varfolomeeva Svetlana R.,
Rumyantsev Alexander G.,
Nakagawara Akira
Publication year - 2019
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.22939
Subject(s) - biology , calcineurin , gene knockdown , neuroblastoma , apoptosis , cancer research , transcription factor , cell growth , microbiology and biotechnology , cell culture , gene , medicine , biochemistry , genetics , transplantation
We previously identified a gain‐of‐function mutation in PPP3CB in a neuroblastoma (NB) with MYCN amplification. Here we investigated the functional and clinical role of PPP3CB in NB. High PPP3CB expression was an independent indicator predicting poor prognosis of NB. Overexpression of wildtype or mutated PPP3CB (PPP3CBmut) promoted cell growth, but PPP3CB knockdown decreased cell growth in NB cells. Forced expressions of PPP3CB and PPP3CBmut activated NFAT2 and NFAT4 transcription factors and inhibited GSK3β activity, resulting in the increase in the expressions of c‐Myc, MYCN, and β‐catenin, which were downregulated in response to PPP3CB knockdown. Treatment with calcineurin inhibitor cyclosporin A (CsA) or FK506 suppressed cell proliferation and induced apoptotic cell death in both MYCN ‐amplified and MYCN ‐non‐amplified NB cell lines. Expression of PPP3CB protein was decreased in response to two calcineurin inhibitors. c‐Myc, MYCN, and β‐catenin were downregulated at the mRNA and protein levels in CsA or FK506‐treated NB cells. Our data indicate that elevated expression of PPP3CB and the expression of its constitutively active mutant contribute to the aggressive behavior of NB tumors and therefore suggest that inhibition of calcineurin activity might have therapeutic potential for high‐risk NB.